Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

This study is examining how menopausal hormone therapy (MHT) and GLP-1 medications (a class of type 2 diabetes and weight-loss drugs) interact to affect blood sugar control and energy use in postmenopausal women with diabetes or prediabetes. **You may be eligible if...** - You are in early postmenopause (confirmed by hormone levels) - You have menopausal symptoms - You have a BMI of 27 or above - You have prediabetes or type 2 diabetes with an HbA1c between 5.7% and 8.5% - You have never used menopausal hormone therapy before **You may NOT be eligible if...** - You have used GLP-1 medications (like Ozempic or Wegovy) in the past 6 months - You have used insulin or other diabetes medications recently - You have had bariatric (weight-loss) surgery - You have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 - You have a history of breast cancer, unexplained vaginal bleeding, blood clots, or porphyria - You are currently using hormonal contraceptives or other hormone therapies Talk to your doctor to see if this trial is right for you.